Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents

Drug Safety

Volumn 27, Issue 6, 2004, Pages 411-420

  Laporte, Joan Ramon ^a,b   Ibáñez, Luisa ^a,b   Vidal, Xavier ^a,b   Vendrell, Lourdes ^b   Leone, Roberto ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLONIXIN LYSINE; DEXKETOPROFEN; DIPYRONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROPYPHENAZONE; ROFECOXIB;

ADULT; ANAMNESIS; ARTICLE; COMMUNITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG UTILIZATION; DUODENUM INJURY; HOSPITAL; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATIENT; PEPTIC ULCER; PRIORITY JOURNAL; RISK ASSESSMENT; SPAIN; STOMACH LESION; UPPER GASTROINTESTINAL BLEEDING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; ODDS RATIO; RISK FACTORS;

EID: 2342489871     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427060-00005     Document Type: Article

References (23)

1. Laporte JR, Carné X, Vidai X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85-9
2. Langman MJS, Well J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
3. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9
4. Henry D, Lim LL-Y, García Rodrìguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6
5. Lewis SC, Langman MJS, Laporte J-R, et al. Dose-response relationships between individual non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320-34
6. Hernández-Díaz S, García-Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9
7. García-Rodrìguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of paracetamol and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570-6
8. Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-81
9. Bruzzi P, Green SB, Byar DP, et al. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122: 904-14
10. Traversa G, Walker AM, Ippolito FM, et al. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology 1995; 6: 49-54
11. García Rodríguez LA, Cattaruzri C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-9
12. Menniti-Ippolito F, Maggini M, Raschetti R, et al. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur J Clin Pharmacol 1998; 54: 393-7
13. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88
14. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. N Engl J Med 1974; 290: 1158-62
15. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993; 53: 485-94
16. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
17. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624-9
18. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-8
19. Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol 2000; 22: 291-8
20. Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997; 48: 623-31
21. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional non-steroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43
22. Llorente Melero MJ, Tenías Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs [in Spanish]. Rev Esp Enferm Dig 2002; 94: 7-12
23. Peris F, Bird HA, Semi U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheumatol Inflamm 1996; 16: 37-45